Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Why Are Airline Stocks Down Today?
10:46am, Tuesday, 12'th Mar 2024
Airline stocks are down today as investors deal with several bits of bad news for the industry on Tuesday! Starting off the negative news today is Delta Air Lines (NYSE:DAL) with its latest quarterly
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
09:30am, Tuesday, 12'th Mar 2024
Acadia Pharmaceuticals (NASDAQ: ACAD ) stock is falling on Tuesday after the company released results from a Phase 3 clinical trial of pimavanserin. Pimavanserin is a drug in development at Acadia P
Acadia Pharma's stock falls 15% after failed drug trial
05:01pm, Monday, 11'th Mar 2024
Shares of Acadia Pharmaceuticals Inc. dropped more than 15% in the extended session Monday after one of the pharma company's drugs failed to meet goals of a late-stage trial about a schizophrenia trea
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
10:15am, Wednesday, 28'th Feb 2024
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues.
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
06:21pm, Tuesday, 27'th Feb 2024
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to loss of $0.26 per share a year ago.
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
11:06am, Tuesday, 20'th Feb 2024
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Culper Research takes short position in Acadia Pharma
11:35am, Thursday, 15'th Feb 2024
Culper Research said on Thursday it has taken a short position on Acadia Pharmaceuticals' stock.
Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
10:42pm, Monday, 22'nd Jan 2024
ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of Prader-Willi Syndrome. PWS is a rare disease characterized by various physical and development
HRMY or ACAD: Which Is the Better Value Stock Right Now?
12:47pm, Thursday, 04'th Jan 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of thes
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
02:17pm, Friday, 29'th Dec 2023
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
04:05pm, Thursday, 21'st Dec 2023
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.
Acadia Pharmaceuticals: Legal Overhang On Nuplazid Removed
03:00pm, Wednesday, 13'th Dec 2023
Shares of Acadia Pharmaceuticals surged after the Court granted a summary judgment in the Nuplazid patent case in its favor. The positive outcome removes an important legal overhang on ACAD stock and
Acadia's Daybue: A Small Patient Pool Making Big Waves
08:19am, Sunday, 10'th Dec 2023
Acadia's Daybue, treating Rett syndrome, shows strong market entry with sales of $90.1 million in the first six months, indicating significant market potential. Acadia's financials are robust with ris
Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS
10:31am, Friday, 01'st Dec 2023
Acadia (ACAD) begins late-stage development of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome.
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)
05:16am, Thursday, 30'th Nov 2023
Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.
